Outsourcing

Chris Spivey is the editorial director of 

Articles

PharmTech Europe discusses technology that enables the “democratization” of mRNA manufacturing with Scott Ripley, general manager, Nucleic Acid Therapeutics and Precision Nanosystems, Cytiva, at the 11th International mRNA Health Conference in Berlin, Germany.

Democratizing GMP Manufacturing for the New Therapeutic Pipeline

Jinhyeok Jeong is senior director of Drug Product Inspection and Packaging at Samsung Biologics.

John Thomas is senior director of Drug Product MSAT at Samsung Biologics.

Demand for efficient tech transfer, as well as compliant on-time delivery, is rising.

Tech Transfer and Regulatory Compliance

CDMOs are actively exploring and leveraging both new and existing technologies to streamline the cell-line development process at every step.

It’s Time for CDMOs to Embrace the CRISPR Advantage

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

The new centralized hub will provide advanced testing of nucleic acids, which is expected to simplify mRNA substance testing.

TriLink BioTechnologies Launches Analytical Sciences Center of Excellence

Feliza Mirasol is the science editor for 

As part of a $30 million investment, Aragen is setting up a new biologics manufacturing facility in Bangalore, India.

Aragen to Establish $30 Million Biomanufacturing Facility in India

Matthew Hewitt is vice-president, technical officer, Cell & Gene Therapy & Biologics at Charles River Laboratories.

Larry Bellot, PhD, is scientific advisor, Cell and Gene Therapy, at Charles River Laboratories.

Chad Andersen is associate director, Manufacturing Sciences & Technology, at Charles River Laboratories.

A look at using best practice tech transfer methods for CGTs to increase process and analytics robustness while being scalable.

Best Practice Tech Transfer Methods for CGTs

Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.

Cellares Expands Agreement with Bristol Myers Squibb for Second CAR-T Program 

The 65,000-square-foot facility is designed with the capacity and capability to help scale the next generation of CGTs for human trials and beyond.

eXmoor pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities 

Editor of Pharmaceutical Technology Europe

Samsung Biologics and Bristol Myers Squibb have further expanded their strategic manufacturing agreement to include the large-scale manufacture of an antibody cancer drug substance. 

Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb

Nuria Gomez Santos, PhD, director, Process and Analytical Development—pDNA, Catalent Cell, Gene & Protein Therapies.

Barry J. Oliver, vice president, Quality, Catalent Cell, Gene & Protein Therapies.

Plasmid DNA (pDNA) is a critical raw material for the manufacture of cell and gene therapies. As this market continues to grow, so too does the demand for high-quality pDNA.

Contract Manufacturing, Biopharmaceutical Production